The ST2/IL-33 axis in immune cells during inflammatory diseases

Brad Griesenauer, Sophie Paczesny

Research output: Contribution to journalReview article

69 Citations (Scopus)

Abstract

Il1rl1 (also known as ST2) is a member of the IL-1 superfamily, and its only known ligand is IL-33. ST2 exists in two forms as splice variants: a soluble form (sST2), which acts as a decoy receptor, sequesters free IL-33, and does not signal, and a membrane-bound form (ST2), which activates the MyD88/NF-κB signaling pathway to enhance mast cell, Th2, regulatory T cell (Treg), and innate lymphoid cell type 2 functions. sST2 levels are increased in patients with active inflammatory bowel disease, acute cardiac and small bowel transplant allograft rejection, colon and gastric cancers, gut mucosal damage during viral infection, pulmonary disease, heart disease, and graft-versus-host disease. Recently, sST2 has been shown to be secreted by intestinal pro-inflammatory T cells during gut inflammation; on the contrary, protective ST2-expressing Tregs are decreased, implicating that ST2/IL-33 signaling may play an important role in intestinal disease. This review will focus on what is known on its signaling during various inflammatory disease states and highlight potential avenues to intervene in ST2/IL-33 signaling as treatment options.

Original languageEnglish (US)
Article number475
JournalFrontiers in Immunology
Volume8
Issue numberAPR
DOIs
StatePublished - Apr 24 2017

Fingerprint

Intestinal Diseases
Graft Rejection
Graft vs Host Disease
Virus Diseases
Regulatory T-Lymphocytes
Interleukin-1
Inflammatory Bowel Diseases
Mast Cells
Colonic Neoplasms
Lung Diseases
Stomach Neoplasms
Allografts
Heart Diseases
Lymphocytes
Ligands
Inflammation
T-Lymphocytes
Membranes
Interleukin-33
Therapeutics

Keywords

  • Cardiac diseases
  • Graft-versus-host disease
  • IL-33
  • IL1RL1
  • Lung diseases
  • ST2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The ST2/IL-33 axis in immune cells during inflammatory diseases. / Griesenauer, Brad; Paczesny, Sophie.

In: Frontiers in Immunology, Vol. 8, No. APR, 475, 24.04.2017.

Research output: Contribution to journalReview article

@article{a37f24b434684eb284fd6b444ac803b6,
title = "The ST2/IL-33 axis in immune cells during inflammatory diseases",
abstract = "Il1rl1 (also known as ST2) is a member of the IL-1 superfamily, and its only known ligand is IL-33. ST2 exists in two forms as splice variants: a soluble form (sST2), which acts as a decoy receptor, sequesters free IL-33, and does not signal, and a membrane-bound form (ST2), which activates the MyD88/NF-κB signaling pathway to enhance mast cell, Th2, regulatory T cell (Treg), and innate lymphoid cell type 2 functions. sST2 levels are increased in patients with active inflammatory bowel disease, acute cardiac and small bowel transplant allograft rejection, colon and gastric cancers, gut mucosal damage during viral infection, pulmonary disease, heart disease, and graft-versus-host disease. Recently, sST2 has been shown to be secreted by intestinal pro-inflammatory T cells during gut inflammation; on the contrary, protective ST2-expressing Tregs are decreased, implicating that ST2/IL-33 signaling may play an important role in intestinal disease. This review will focus on what is known on its signaling during various inflammatory disease states and highlight potential avenues to intervene in ST2/IL-33 signaling as treatment options.",
keywords = "Cardiac diseases, Graft-versus-host disease, IL-33, IL1RL1, Lung diseases, ST2",
author = "Brad Griesenauer and Sophie Paczesny",
year = "2017",
month = "4",
day = "24",
doi = "10.3389/fimmu.2017.00475",
language = "English (US)",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - The ST2/IL-33 axis in immune cells during inflammatory diseases

AU - Griesenauer, Brad

AU - Paczesny, Sophie

PY - 2017/4/24

Y1 - 2017/4/24

N2 - Il1rl1 (also known as ST2) is a member of the IL-1 superfamily, and its only known ligand is IL-33. ST2 exists in two forms as splice variants: a soluble form (sST2), which acts as a decoy receptor, sequesters free IL-33, and does not signal, and a membrane-bound form (ST2), which activates the MyD88/NF-κB signaling pathway to enhance mast cell, Th2, regulatory T cell (Treg), and innate lymphoid cell type 2 functions. sST2 levels are increased in patients with active inflammatory bowel disease, acute cardiac and small bowel transplant allograft rejection, colon and gastric cancers, gut mucosal damage during viral infection, pulmonary disease, heart disease, and graft-versus-host disease. Recently, sST2 has been shown to be secreted by intestinal pro-inflammatory T cells during gut inflammation; on the contrary, protective ST2-expressing Tregs are decreased, implicating that ST2/IL-33 signaling may play an important role in intestinal disease. This review will focus on what is known on its signaling during various inflammatory disease states and highlight potential avenues to intervene in ST2/IL-33 signaling as treatment options.

AB - Il1rl1 (also known as ST2) is a member of the IL-1 superfamily, and its only known ligand is IL-33. ST2 exists in two forms as splice variants: a soluble form (sST2), which acts as a decoy receptor, sequesters free IL-33, and does not signal, and a membrane-bound form (ST2), which activates the MyD88/NF-κB signaling pathway to enhance mast cell, Th2, regulatory T cell (Treg), and innate lymphoid cell type 2 functions. sST2 levels are increased in patients with active inflammatory bowel disease, acute cardiac and small bowel transplant allograft rejection, colon and gastric cancers, gut mucosal damage during viral infection, pulmonary disease, heart disease, and graft-versus-host disease. Recently, sST2 has been shown to be secreted by intestinal pro-inflammatory T cells during gut inflammation; on the contrary, protective ST2-expressing Tregs are decreased, implicating that ST2/IL-33 signaling may play an important role in intestinal disease. This review will focus on what is known on its signaling during various inflammatory disease states and highlight potential avenues to intervene in ST2/IL-33 signaling as treatment options.

KW - Cardiac diseases

KW - Graft-versus-host disease

KW - IL-33

KW - IL1RL1

KW - Lung diseases

KW - ST2

UR - http://www.scopus.com/inward/record.url?scp=85018439059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018439059&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.00475

DO - 10.3389/fimmu.2017.00475

M3 - Review article

AN - SCOPUS:85018439059

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - 475

ER -